„BIOMED-LUBLIN” S.A.

About „BIOMED-LUBLIN” S.A.

“BIOMED-LUBLIN” S.A. is a Polish biotechnology company with a long history focused on promoting health and saving people’s lives. We are a trusted name in the healthcare sector consistently serving the needs of millions of patients providing high quality, affordable and innovative medicines across therapeutic areas. “BIOMED-LUBLIN” S.A. manufactures, develops new and improves existing biotech medicinal products meeting all necessary quality requirements like GMP, evidenced by the relevant certificates. Areas of involvement are oncology, gynecology, urology, proctology, immunotherapy. Our specialty are original prescription medicinal products.

  • PL
  • 2021
    On CPhI since
  • 1
    Certificates
  • 100 - 249
    Employees
Manufacturer/Innovator
Contact info

Products from „BIOMED-LUBLIN” S.A.

  • Onko BCG 100

    Product Onko BCG 100

    The product is intended for treatment of superficial, epithelial non-invasive urothelial carcinomas (carcinoma urotheliale Ta, Tis, T1)
  • Onko BCG 50

    Product Onko BCG 50

    The product is intended for treatment of superficial, epithelial non-invasive urothelial carcinomas (carcinoma urotheliale Ta, Tis, T1)

  • BCG 10 anti-tuberculosis vaccine

    Product BCG 10 anti-tuberculosis vaccine

    BCG 10 Anti-Tuberculosis Vaccine is used for protective vaccinations against tuberculosis.
  • Distreptaza

    Product Distreptaza

    1. Supportive treatment of pelvic inflammatory disease (PID) - inflammatory diseases of the ovaries, fallopian tubes and endometrium,2. Adhesions after abdominal surgical procedures,
    3. Acute haemorrhoidal disease and chronic haemorrhoidal disease,
    4. As an supportive treatment in perirectal abscesses and fistulas with extensive inflammatory infiltration.
  • Gamma anty-D 150

    Product Gamma anty-D 150

    Preventing immunisation with Rh(D) factor in the case of Rh(D)-negative women. - Pregnancy/giving birth to an Rh(D)-positive child
    For administration after childbirth, during pregnancy and after the abortion of a foetus after the 12th week of gestation, in the threat of immature or premature labour, and after diagnostic amniocentesis after the 12th week of pregnancy.

  • Gamma anty-D 50

    Product Gamma anty-D 50

    Preventing immunisation with Rh(D) factor in the case of Rh(D)-negative women.
    Miscarriage/threatened miscarriage, ectopic pregnancy

  • Gamma anty-HBs 200

    Product Gamma anty-HBs 200

    Immunoprophylaxis against Hepatitis B

    -        newborns of mothers with Hepatitis B

    -        children up to 50 kg of weight, especially exposed to the risk of HBV nonsocomial infection.